Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Exane BNP Paribas Downgrades Best Buy Co to Neutral

Exane BNP Paribas analyst Chris Bottiglieri downgrades Best Buy Co (NYSE:BBY) from Outperform to Neutral.

byBenzinga Newsdesk

January 12, 2023

1 minute read

Exane BNP Paribas analyst Chris Bottiglieri downgrades Best Buy Co (NYSE:BBY) from Outperform to Neutral.

Jefferies Maintains Hold on Moderna, Lowers Price Target to $325

By Benzinga Newsdesk

November 5, 9:50 AM

Jefferies analyst Michael Yee maintains Moderna (NASDAQ:MRNA) with a Hold and lowers the price target from $375 to $325.

MRNA

Keefe, Bruyette & Woods Downgrades Ameriprise Financial to Market Perform, Announces $325 Price Target

By Benzinga Newsdesk

December 19, 5:41 AM

Keefe, Bruyette & Woods analyst Ryan Krueger downgrades Ameriprise Financial (NYSE:AMP) from Outperform to Market Perform and announces $325 price target.

AMP

Mizuho Maintains Neutral on EnLink Midstream, Raises Price Target to $13

By Benzinga Newsdesk

May 27, 6:49 AM

Mizuho analyst Gabriel Moreen maintains EnLink Midstream (NYSE:ENLC) with a Neutral and raises the price target from $12 to $13.

ENLC

News

Musk Wants To Delay Twitter Trial

By Benzinga Newsdesk

August 30, 12:42 PM

- Reuters Citing Court Records

TWTR

Exane BNP Paribas Downgrades Best Buy Co to Neutral

Related Posts

Jefferies Maintains Hold on Moderna, Lowers Price Target to $325

Keefe, Bruyette & Woods Downgrades Ameriprise Financial to Market Perform, Announces $325 Price Target

Mizuho Maintains Neutral on EnLink Midstream, Raises Price Target to $13

Musk Wants To Delay Twitter Trial